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Brain metastasis are the most common neoplastic lesions of the nervous system. Many cancer patients are diagnosed on the basis
of a ﬁrst clinical presentation of cancer on the basis of a single or multiple brain lesions. Brain metastases are manifestations of
primarydisease progressionand often determinea poor prognosis. Not all patients with a brain metastases undergo surgery: many
are submitted to alternative or palliative treatments. Management of patients with brain metastases is still controversial, and many
studies have been developed to determine which is the best therapy. Furthermore, management of patients operated for a brain
metastasis is often diﬃcult. Chemotherapy, stereotactic radiosurgery, panencephalic radiation therapy, and surgery, in combina-
tion or alone, are the means most commonly used. We report our experience in the management of a ten-year series of surgical
brain metastasis and discuss our results in the preoperative and postoperative management of this complex condition.
1.Introduction
Brain metastases represent the most frequent type of in-
tracranial tumors, being a common complication of cancer.
The most common sources of brain metastases are lung,
breast, or melanoma, and in as many as 15% of patients,
primitive localization remains uncertain [1]. The frequency
of brain metastases has increased over time, probably as
a result of advances in neuroimaging procedures and im-
provements in the treatment of primary and systemic cancer
disease. Though nowadays, head CT studies and MRIs oﬀer
high quality imaging, there are not characteristic features
which enable us to distinguish brain metastases from pri-
mary malignant brain tumors or nonneoplastic conditions
[1, 2]. Tissue biopsy is necessary in patients with an un-
identiﬁed primary tumor before radiotherapy and/or chem-
otherapy. Most patients who develop brain metastases have
a relatively short prognosis even if initial treatment is often
successful. Survival is determined by the progression of sys-
temic disease or by ineﬀective control of neurological disease
[3, 4].
Several factors are important for determining prognosis
and have been combined to determine survival scores: a high
Karnofsky performance Status, a single brain metastasis,
absenceoffurthersystemicmetastases,satisfactorycontrolof
primary tumor and younger age at diagnosis. Prognosis has
beendeterminedaccordingtothesefactors,amongothers,in
the recursive partitioning analysis (RPA) classiﬁcation [5].
Treatment options in patients with newly diagnosed
brain metastases have improved over the years, and the
choice of therapy should take into account patient condi-
tions, number, size, and histology of metastases. The com-
bination of surgery and whole-brain radiotherapy (WBRT)
is superior to WBRT alone for the treatment of single brain
lesions in patients with good prognostic scores [6]. A total
surgical exeresis can resolve acute problems due to increased
intracranial pressure and irritative and focal neurological
deﬁcits. A valid alternative can be radiosurgery, with or
without WBRT, if lesion diameter is under 3cm. Moreover,
radiosurgeryenablestreatmentsurgicallyinaccessiblemetas-
tases [7].2 ISRN Surgery
2. Prognostic Factors
2.1. Histology. Histology of primary tumor is a very impor-
tantprognosticfactor.Wecanﬁnddiﬀerentkindofneoplasia
whichcanbedividedaccordingtoresponseagainsttherapies.
We propose to deﬁne tumors in base of radiosensitivity. Ra-
dioresistant tumors are kidney cancer and melanoma [8].
They are considered radioresistant, because they tend to not
respond to WBRT. They could be treated by SRS or surgery
achievingagoodlocalcontrol[1,7].Inthosetumors,surgery
may could be preferred to achieve better local control and a
rapid relieve from symptoms, but no evidence can support
our opinion. At this time, metastases considered to have
worst prognosis as possible develops from lung tumors, renal
tumors, and melanoma [8].
Moreover, not all tumors have a surgical indication:
tumors such as lymphomas or small cells lung carcinoma
(SCLC) must not be treated. Particularly, lymphomas are
treated with high dosage steroids, whereas SCLC is treated
with WBRT. Diﬀerent authors suggest use of prophylactic
brain irradiation in patients aﬀe c t e db yS C L C[ 9]. In these
cases, the only reason determining a surgical exeresis is
characterized by life-threatening intracranial hypertension.
2.2. KPS, RPA, and Other Grading Scales. The most impor-
tantprognosticfactoraﬀectingprognosisisbelievedtobethe
Karnofsky performance status (KPS). It has been seen that
patients with a low-performance status at diagnosis have a
worse outcome than others with better KPS [5, 8]. Another
parameter aﬀecting prognosis seems to be the age at diagno-
sis.
(i) RPA (recurrence partitioning analysis) relates KPS
with age at presentation [5]. Cutoﬀ is ﬁxed at 65 years old.
Another parameter taken into account is the absence or pres-
ence of disease progression. Obviously, uncontrolled disease
relates with poor prognosis [5]. RPA is the most important
evaluationscale,atpresenttime,fordividingpatientsaccord-
ing to prognostic classes. The subdivision into 3 classes
makes it simple and easy to use, and it is nowadays com-
monly used to assess surgical eligibility for patients. In addi-
tion, good RPA often indicates a better response and compli-
ance to adjuvant therapies, meaning a relative good outcome
in surgically treated patients. On the contrary, low RPA
indicates a progression of the primary disease and a probable
worse response to adjuvant therapies with a consequent
worsesurgicaloutcome.RPAisusefultocandidatetosurgery
asymptomatic or low-symptomatic patients, but, in our
opinion,ithassomecharacteristicsthatdonotfulﬁlltheclin-
ical needs. Further considerations will be discussed below.
Severalotherprognosticscaleshavebeendescribedinthe
literature. In particular, we report the SIR and the GPA
grading scores.
(ii)SIR(scoreindexforradiosurgeryinbrainmetastases)
is a prognostic score index for patients treated with SRS.
It classiﬁes patients into 3 categories according to 5 major
prognostic factors: KPS, age at presentation, extracranial dis-
ease status, number of brain lesions, and largest brain lesion
volume. The SIR has the advantage of including, diﬀerently
from the RPA, the number of brain metastases, which is now
a proven high-signiﬁcance prognostic factor. In a retrospec-
tive study conducted on patients undergoing radiosurgery,
SIR demonstrated a signiﬁcant correlation with survival,
showing even a superior accuracy in assessing survival than
RPA [10]. Its disadvantage consists of the required calcula-
tion of the largest lesion’s volume. In fact, this parameter is
oftenassessedonlyatthetimeofradiosurgery.Therefore,the
SIR seems to miss the point of a prognostic index, which is
to predict survival before any treatment decision is made in
order to guide the treatment choice itself.
(iii) GPA (graded prognostic assessment) is a prognostic
index based on the RTOG (radiation therapy oncology
group) database. Itis the sum of 3 scores, taking into account
4 prognostic factors: age at presentation, KPS, extracranial
metastases, and the number of brain metastases. The GPA,
whencomparedtootherprognosticscores,hastheadvantage
ofeliminatingcomponentsthatarediﬃculttoquantify(such
as primary tumor and extracranial disease control), since
they are inﬂuenced by diagnostical means. Furthermore,
unlike SIR, parameters depending on treatment factors such
as the lesion volume are considered. In a recent study, GPA
was found to have a prognostic value similar to the RPA and
greater than other indices [11].
In Table 1, a brief comparison between the three main
prognostic scores is shown.
2.3.ExtracranialLocalizationsandDiseaseControl. Extracra-
n i a lm e t a s t a s e si ns y s t e m i cc a n c e rr e l a t ew i t hap o o rp r o g -
nosis [5]. This is a fundamental factor in treatment choice.
Patients at a terminal stage of disease are not eligible for
surgery, WBRT or SRS. Only therapy with high dosage of
steroids and palliative care can be taken into consideration,
as survival in these patients is estimated to be only a few
months. Treatment of patients with good performance status
and stable extracranial disease can be problematic consider-
ing that systemic cancer gives rise to brain metastases and
extracranial localizations [12].
3. CurrentTreatment Options
Actual treatment options for brain metastases include sur-
gery, stereotactic radiosurgery (SRS), whole brain radiation
therapy (WBRT), and chemotherapy.
(i) WBRT was the ﬁrst and, for a long time, elective treat-
ment strategy for brain metastases [13]. Nowadays, its role is
controversial,asithasbeenproventobeassociatedwithhigh
brain toxicity determining severe cognitive impairments,
particularly in learning and memory functions [14], and
causes a loss in functional autonomy [4]. WBRT remains the
treatment of choice for patients with single or multiple brain
lesions not selectable for surgery or SRS. On these patients,
WBRT results in a median survival period of 3 to 6 months
[15]. Diﬀerences in dose, timing and fractionation have been
studied but do not seem to signiﬁcantly inﬂuence median
survival time [16, 17]. In patients submitted to surgery or
SRS, the association of WBRT relates to a better local
disease control when compared to surgery or stereotactic ra-
diosurgery alone. In addition, WBRT can be used as life-
saving treatment. Anyhow, it has been shown that WBRTISRN Surgery 3
Table 1: Summary of three main diﬀerent prognostic indexes, recursive partitioning analisys (RPA), score index for radiosurgery in brain
metastases (SIR), graded prognostic assessment (GPA).
(a) Recursive partitioning analysis (RPA)
Class I Class II Class III
Age (years) <65
All patients not in Class I or III <70 KPS ≥70
Control of primary tumor Yes
Extracranial metastases No
(b) Score index for radiosurgery in brain metastases (SIR)
Score 0 Score 1 Score 2
Age (years) ≥60 51–59 <= 50
KPS ≤50 60–70 >70
Systemic disease status Progressive disease Progressive-stable disease Complete clinical remission—no evidence of disease
Largest lesion volume (cm3) >13 5–13 <5
Number of lesions ≥32 1
(c) Graded prognostic assessment (GPA)
Score 0 Score 0.5 Score 1
Age (years) >60 50–59 <50
KPS <70 70–80 90–100
Number of CNS metastases >32 - 3 1
Extracranial metastases Present — None
fails to improve or to signiﬁcantly increase global survival
rate. Moreover, a gain in survival is associated with worse
neurological condition [4]. It is still unclear if WBRT should
be used as an adjuvant treatment following surgery or SRS.
Kocher and colleagues proposed a close follow-up period
after either surgery or SRS with brain MRI, using WBRT as
lifesaving treatment [4]. The role of WBRT in patients with
a low RPA is still to be established. In a recent study from
Komosinska et al., WBRT determined to have more side
eﬀects than beneﬁts without improvement of survival rate
and quality of life [18]. Randomized studies about long-
time survivors may give more accurate information about
neurotoxicity from WBRT.
(ii) SRS consists in a single high-dose multiple conver-
gent radiation delivery to a small target volume, minimizing
the damage to surrounding brain tissue. It allows treatment
of metastases at almost any location in both radiosensitive
and radioresistant tumors [7]. According to several au-
thors, SRS determines an inferior local disease control com-
pared to surgery alone [1, 19, 20]t h o u g hi ti sl e s si n v a s i v e .
Nevertheless, it seems to be aﬀected by a similar peri-
operative mortality rate [1]. Elective indications are small
lesions (inferior or equal to 3cm) without mass eﬀect and
with an assumed diagnosis. Important disadvantages are
requirement of long-term high-dosage steroids, radionecro-
sis (needing an additional diagnostical and therapeutical
management) and signiﬁcant patient prostration, with poor
possibilities of recovery. SRS can also be used as an adjuvant
or a lifesaving treatment. SRS alone is considered to have
the same impact on survival rate as surgery followed by
SRS. Moreover, SRS combined with WBRT show the same
outcome as surgery and WBRT [21].
(iii) Chemotherapy plays an important role for systemic
disease control: it is not indicated as a primary therapy for
brain metastases [3]. Ewend et al. used Carmustine polymer
wafers as local chemotherapy after surgical resection. Each
patient also received WBRT; local recurrence rate was ex-
tremely low (0%), and survival rate was 33% at 1 year and
25% at 2 years [22]. Furthermore, association of Temozolo-
mide and WBRT has not improved survival rate in several
studies [23, 24]. Fotoemustine and Temozolomide have been
used as single agents or in combination for the treatment of
melanoma metastases with poor results [25–28]. Develop-
ment of new strategies, such as local pharmacological agents,
may give way to new therapeutical options in the near future.
(iv) Surgery is the most invasive treatment compared to
the other strategies. On the other hand, it enables deﬁnitive
histological diagnosis (which is important to set further ad-
juvant therapies). Moreover, surgical exeresis of the lesion
relieves the patient from neurological conditions due to
intracranial hypertension (determined by the mass eﬀect of
the lesion and the surrounding edema). Contraindications
are the presence of uncontrolled disease, very poor prognosis
at presentation, and deteriorated clinical conditions. Patients
with multiple lesions are often submitted to SRS. Anyhow,
Paek et al. reported that patients with 2 or 3 lesions, under-
going exeresis of the dominant lesion and WBRT, showed an
equal survival rate as patients with a single lesion [29]. These
results were conﬁrmed by Stark and colleagues [30]. Another
study performed by Bindal et al. showed better survival rate4 ISRN Surgery
in patients with resection of all lesions in comparison to
patients who underwent exeresis of only dominant lesion
[31]. Nevertheless, multiple lesions (>3) are not considered
to be surgically treatable [1]. Several additional problems
are debated for surgery, in particular the type of exeresis
(piecemeal versus en block). In a retrospective study of MD
Anderson Cancer Centre, piecemeal resection seemed to
increase the risk of dissemination to the leptomeninges
(LMD); such risk is higher in posterior fossa lesions after
either surgery or SRS [32]. A second study from MD Ander-
son group demonstrated a higher risk of local recurrence
in brain metastasis treated with piecemeal resection than in
those treated with en block resection [33]. Surgery followed
by WBRT certainly determines a more eﬀective treatment
in terms of local and distant recurrence [1, 6]. Contrasting
results are reported in studies comparing diﬀerent treatment
options, such as SRS and WBRT versus surgery and WBRT
[6]. Therefore, the role of adjuvant therapies after surgical
resection is still unclear: there are no clinical studies compar-
ing the results of surgery and/or WBRT versus surgery and
SRS. Finally, we lack information concerning patients with
multiple metastases, low KPS, and uncontrolled extracranial
disease.
4.MaterialandMethods
Patients with cerebral metastases suﬀer systemic cancer
which is often related with a poor prognosis. The neurosur-
gical procedure is an invasive treatment, and it can be asso-
ciated with invalidating complications such as hemiplegia or
aphasia.Theadvancingofnewandlessinvasivetechnologies,
particularly SRS, have progressively diminished the role of
surgery for the treatment of brain metastases [7]. In our
institution, brain metastases are surgically treated according
to the following criteria:
(i) necessity of deﬁnitive histological diagnosis,
(ii) relatively good prognosis,
(iii) absence of extracranial metastatic localizations,
(iv) life-threatening intracranial hypertension.
In our opinion, these criteria take into account clinical
necessities.Patientswhodidnotmeetthesecriteriaweresub-
mitted to palliative cares.
Surgical exeresis was performed mostly on single lesions.
KPS is a useful parameter for assessing patient’s prognosis.
However, surgical indication in our series was not strictly
based on KPS, for several reasons. First, preoperative KPS,
is inﬂuenced by reversible pathological conditions, such as
brainedema,intracranialhypertension,neurologicaldeﬁcits,
or epilepsy. Second, posterior fossa lesions often represent a
life-threatening condition, and it is not always easy to over-
run such this factor. Third, surgical intervention has become
a standard procedure, and complications have diminished
throughyears.Fourth,surgerycanrelieveorevensolvepath-
ological conditions (aﬀecting KPS at presentation) reported
above. Last, a histological determination can be assessed.
We do not perform surgical procedures in patients with
uncontrolledextracranialdisease,inpatientsathighanesthe-
siological risk, or in patients with more than 3 lesions which
are not resectable through one craniotomy. Age is considered
Table 2: Number of patients according to primary tumor histology
and dominant lesion localization.
Histology Patients
Lung 99
Kidney 22
Bowels 16
Melanoma 14
Breast 12
Liver 2
Prostate 1
Testicle 1
Bladder 1
Ovary 1
Uterus 1
Unknown 34
Total 204
Localizations Number of main lesions
Frontal 66
Posterior fossa 54
Parietal 35
Temporal 26
Occipital 17
Sella 4
Meninges 2
Total 204
a debatable contraindication, since many patients over 65
years of age can sustain general anesthesia. Therefore, we
believe that age is indeed a predictive factor on prognosis,
but 65 years should not be an absolute cutoﬀ. Furthermore,
patients presenting with one to 3 lesions under 3cm in
diameter, without neurological deﬁcits and an assumed his-
tological diagnosis, were sent to SRS, according to scientiﬁc
evidences [6].
5. Results
5.1. Our Surgical Series. We report a ten-year series of pa-
tients aﬀected by brain metastases who were submitted to
surgery. We performed surgical exeresis or biopsy of brain
metastasison204patients(128malesand76females)admit-
ted at our institution between 2000 and 2009. Surgical exere-
sis was performed en block in all cases. Average age was 59.7
years (range 24–85 years). Twenty-eight patients had more
than one lesion, and 8 patients underwent a stereotactic
biopsy. We excluded patients submitted to SRS or WBRT
before surgery. In 89 cases, a primary tumor diagnosis was
known, while in the remaining 115 cases, brain metastases
were the ﬁrst clinical manifestation of cancer. Histology and
localizations of lesions are reported in Table 2.M o s tb r a i n
metastases were from lung (99), followed by kidney (22),
bowels (16), melanoma (14) and breast (12) cancer. In 34
cases (16.7%), the source of primary tumor remained
unknown. All patients were classiﬁed according to Gaspar’sISRN Surgery 5
Adjuvant therapies
WBRT; 24.18%
No therapy;
25.27%
Gamma-
knife; 8.79%
WBRT + CHT;
32.97%
CHT; 8.79%
Figure 1: Adjuvant treatments delivered to patients. 82 (33%)
patients underwent WBRT plus chemotherapy, 45 (24.2%) patients
only WBRT, 19 (8.8%) patients only chemotherapy and 13 (8.79%)
patients were sent to SRS or cyber knife. 45 (25.3%) patients have
been only followed up or have been sent to palliative cares.
8.8
10.4
22.3
13 12.8
0
5
10
15
20
25
SRS WBRT CHT No therapy WBRT +
CHT
Figure 2: Average survival related to adjuvant therapies.
Table 3: Average and median survival in patients with brain metas-
tases according to RPA index. Note diﬀerences between average and
median survival probably due to clinical inﬂuencing factors not
taken into account.
RPA Average survival Median survival
Class I 19.71 10.3
Class II 16.4 8.3
Class III 10.27 3.6
recursive partitioning analysis (RPA) classes. In our series, 91
patients were in class I, 50 patients in class II and 63 patients
inclassIII.KPSwascalculatedatadmission;averageKPSwas
79.8. Perioperative death rate was <2%.
After surgical resection, patients were selected for diﬀer-
ent further medical treatments in agreement with the oncol-
ogists. In particular, 82 patients were submitted to WBRT
and chemotherapy, 45 patients to only WBRT, 19 patients
were submitted to only chemotherapy, and 13 patients were
to SRS or cyber knife. Fourty-ﬁve patients had no further
treatment or were oﬀered palliative cares. The latter strategy
ismoreoftenthechoiceinelderlypatientsorinpatientswith
extracranial disease (see Figure 1).
We considered followup until November 2010. Median
survival was 10 months (range 1–80 months). Survival ac-
cording to adjuvant therapies is shown in Figure 2.R e c u r -
rence rate was 11.27%; 6 patients who did not receive
Table 4: Average and median survival in patients with brain metas-
tases according to primary tumor histology. Note diﬀerences
between average and median survival probably due to inﬂuencing
factors not relating only with histology.
Histology Average survival Median survival
Breast 19.01 10.3
Bowels 11.17 11.0
Kidney 32.9 6.5
Lung-NSCLC 19.75 11.15
Lung-SCLC 10.8 10.25
Melanoma 10.83 8.0
Unknown 11.64 3.6
radiotherapy after surgery and with a good disease control
underwent a second craniotomy, and only one underwent a
third craniotomy. We considered survival rate according to
histology and RPA classes (see Tables 3 and 4 and Figures 3
and 4). RPA class I-patients showed a better prognosis than
others, with an average survival of 19.7 months (median 10.3
months).Thisresultmayberelatedtoabetterreliefaftersur-
gery and consequently to a better compliance to adjuvant
treatments. RPA class II-patients had an intermediate prog-
nosis, with an average survival of 16.4 months (median 8.6
months) and RPA class III-patients showed an average sur-
vival of 10.3 months (median 3.6 months).
6. Discussion
6.1. RPA Pitfall. RPA and other grading scales, such as SIR
and GPA, take into account mainly KPS, extracranial disease,
numberoflesions,orlesion’svolume.Allmaingradingscales
do not take into account patient’s neurological conditions.
For example, intracranial hypertension due to severe edema
determines a rostrocaudal deterioration. This is related to a
decreased KPS. Surgical debulking results in an increase of
KPS because functional structures (corticospinal tract, Broca
or Wernicke’s areas) are relieved from compression with an
improvement of neurological condition. Moreover, surgical
decompression can reverse distress of the ascending reticular
activating system, improving a confusional state or coma
which were responsible for a low preoperative KPS.
An additional problem is the localization of metastatic
lesions: supratentorial lesions present diﬀerent clinical prob-
lems and determine several cerebral dysfunctions. Further-
more, posterior fossa tumors enclose two important prob-
lems:theydeterminelife-threateningconditionsandtheyare
associated with a high risk of leptomeningeal dissemination
(LMD). LMD is considered to have a very poor prognosis (3-
4 months) due to the lack of treatment possibilities [34].
Therefore,surgeryrepresentsaneﬀectivestrategyconsid-
ering not only prognostic factors, but also clinical status. In
our opinion, KPS is a good performance status index, but it
needs to be reconsidered and adapted according to reversible
neurological conditions. Preoperative KPS diﬀers from post-
operative KPS: surgery improves neurological deﬁcits,
edema, and seizures and leads to a deﬁnitive histological
diagnosis.Finally,oncologicalpatientscandevelopaprimary6 ISRN Surgery
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Figure 4: Average survival according to RPA.
brain tumor or another neoplasia. Patchell and collegues
have shown that 11% of patients with brain metastases may
have nonmetastatic lesions such as an abscess or a primary
brain tumor [35].
6.2. Which Treatment? Literature reports diﬀerent studies
concerning the use of surgery, SRS and WBRT. The main
debate is upon the beneﬁts and risks of surgery versus radio-
surgery. In patients with good RPA (class I or II), indications
for SRS and surgery are well deﬁned: SRS is the treatment
of choice in patients with a highly probable diagnosis, lesion
size <3cm and without mass eﬀect (<1cm brain shift) [1].
Patients with intracranial hypertension usually have a low
KPS, consequently inﬂuencing a low RPA. Such patients
would probably take great advantage from intracranial
decompression. Therefore, as remarked above, some RPA
class III-patients may be treated surgically. Systemic disease
control is, in our opinion, an important factor inﬂuencing
surgical indication. Patients with uncontrolled extracranial
disease cannot be eligible for an elective surgical treatment,
with the important exception of patients with posterior fossa
lesions and clinical signs of cerebellar herniation. Finally,
patients with low RPA are commonly treated with WBRT. In
a recent study, however, the role of palliative WBRT in RPA
class III-patients is debated: according to Komosinska, such
patients probably do not beneﬁt from WBRT [18].
6.3. Implications of Treatment on Cognitive Functions. The
inﬂuence of radiation therapies on cognitive functions is
a recent matter of study due to the progressive increase in
survival and eﬃcacy of treatments. As reported above, SRS
and WBRT are related with cognitive impairment [4, 14].
Particularly, radiation therapy is characterized by several
adverse reactions (classiﬁed as acute, subacute, and delayed)
that foreclose the delivery of high-dose X-rays [36, 37].
Such side eﬀects can develop either after WBRT and SRS.
Cognitive impairment is a delayed toxic reaction becoming
more evident in long survivors [13]. Risk factors related
to cognitive impairment are fraction size >2Gyandwhole
b r a i nR T .A n y h o w ,s u c hf a c t o r sh a v en o tb e e ne x t e n s i v e l y
analysed on randomized trials [37]. As possible additional
risk factors, we report the cerebral volume irradiated and
a long time interval after treatment [37]. Particularly, the
necessity to deliver WBRT in the immediate postoperative
period still needs to be assessed. Kocher and colleagues
proposed to delay brain irradiation preferring a closer ra-
diological followup with short intervals between brain
metastases’ treatments and the MRI scans and consider
WBRT as a terminal option in cases of recurrence or new
localizations [4]. Radionecrosis is a further delayed toxic
eﬀectofradiations.Itinvolvesmainlythewhitematter,andit
develops after both WBRT and, less frequently, SRS [13, 38].
Diﬀerential diagnosis is diﬃcult, since no eﬀective diagnos-
tic technique for distinguishing radionecrosis from tumor
recurrence is available [39, 40].
6.4. Considerations on Survival. T h es u r v i v a ld a t as h o w na r e
inﬂuenced by diﬀerent clinical parameters which do not
oﬀer an eﬀective prediction on prognosis. Particularly, the
distinction between class II and class III-patients fails to
be completely clear. In fact, class III-patients could have
had an intracranial hypertension determining a lower KPS
(<70), while class II-patients could have had a good KPS but
uncontrolled or only partially controlled metastatic disease,
or they could have been more than 65 years old. Considering
survival according to histology (Table 3), we noticed that
survival rate is strongly related to histological diagnosis,
a factor which is not taken into account by RPA or other
grading scores. This fact can be obtained comparing average
with median survival rate (Tables 3 and 4). Diﬀerences may
relate with other parameters that are not taken into account
considering histology or RPA only. For example, in radiore-
sistant tumors, surgery may be preferred to SRS in order to
achieve a better local control and a rapid relief of symptomsISRN Surgery 7
even if we have no evidence to support our opinion. Clinical
parameters are not taken into account in prognostic indexes
such as disease-free interval. As a matter of fact, in our series,
many patients were cancer-free for a long term before devel-
oping brain metastases, and this ﬁnding seems to relate to a
better prognosis. Patients developing brain metastases after a
long free survival period show a better prognosis than those
with a history of rapid development of brain metastases [8,
41, 42]. We also observed a better outcome and survival rate
in patients with a long history of neoplastic disease (unpub-
lished data). For this reason, we believe that RPA classes are
useful for selecting patients for WBRT but incomplete for
assessment of surgical indications. We, therefore, believe
RPA analysis may be improved with some adjustments, for
example, introducing a risk stratiﬁcation based on histology,
neurological deﬁcits, intracranial hypertension, and long
disease-free interval between primary tumor diagnosis and
the onset of brain metastasis.
7. Conclusions
Inconclusion,accordingtoouropinion,surgerystillremains
the best therapeutical possibility for brain metastases, as it
provides a deﬁnite histological diagnosis, it relieves epilepsy,
and it allows fast debulking of suﬀering nervous structures,
determining an improvement of KPS and a better overall
prognosis. These functions cannot be relieved by SRS alone,
which remains an eﬀective treatment for lesions without
deﬁnitive histological diagnosis, poor edema, pharmaco-
logically treated epilepsy, and without neurological deﬁcits.
Finally, we believe that more accurate scoring grades should
be developed, particularly a grading system taking into
account reversible patient’s clinical conditions.
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